SAN DIEGO & ROCHESTER, Minn.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced it has entered an agreement with Mayo Clinic to make advancements in next-generation sequencing technology with the intent to accelerate Mayo’s delivery of genetic and genomic expertise.
Together, the organizations plan to integrate existing services and software tools and employ new, innovative solutions to improve Mayo Clinic’s reporting workflows for researching inherited disease, enabling Illumina to develop an informatics platform and knowledge base that can improve and automate genomic interpretation.
As part of the agreement, Mayo Clinic will implement BaseSpace Clarity LIMS in specific laboratories to provide testing of the tool. BaseSpace Clarity LIMS is a system to provide comprehensive workflow tracking and integration in laboratories. Mayo Clinic will also deploy and provide feedback on its use of BaseSpace Sequence Hub, a cloud-based genomics computing environment for data analysis and management, and BaseSpace Variant Interpreter, a cloud-based interpretation and reporting platform designed to decrease the time and effort required to assess biological insight from genomic data. The software solutions will be piloted by Mayo Clinic to annotate and interpret genetic variants with regard to their potential role in the development and progression of diseases.
“Through this relationship, we will be able to generate large volumes of genomic information, interrogate the data, and then compare it to what’s known about those variants and those genetic aberrations in real time, saving our geneticists time,” said William Morice, II, M.D., Ph.D., chair of Mayo’s Department of Laboratory Medicine and Pathology and president of Mayo Medical Laboratories. “We are pleased to work with Illumina and to leverage each other’s expertise in genetic sequencing and analysis.”
“Mayo Clinic has been at the forefront of advanced medical research and patient care for a long time,” said Sanjay Chikarmane, senior vice president and general manager of Illumina Enterprise Informatics. “BaseSpace Informatics Suite has the ability to provide a cloud-based software solution that can manage, analyze and interpret data automatically. We’re pleased that our offering will help Mayo Clinic make sense of genomic data faster and more accurately.”
About BaseSpace Informatics Suite
BaseSpace Informatics Suite tools and solutions allow users to manage and process data in one, secure unified system, from laboratory information management and data storage, to analysis and interpretation. This seamless integration between tools and solutions enables users to save time by automating the process from the initial sample intake to getting a report about genomic data, and provides high-quality, accurate information with a fast turnaround time.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education, and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/.
About Mayo Medical Laboratories/Department of Laboratory Medicine and Pathology
The Mayo Clinic Department of Laboratory Medicine and Pathology and its reference laboratory Mayo Medical Laboratories provide advanced laboratory testing and pathology services to support 5,000 health care organizations around the world. Revenue from this testing is used to support medical education and research at Mayo Clinic, a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. Complemented by collaborations with diagnostic and biotechnology companies, the department maintains a robust diagnostic test-development program, launching more than 150 new tests each year.
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.